Regencell Bioscience Holdings Ltd (RGC) Share Price

Buying here

Back to where it belongs?? Trash??

So much fun

How fun

Lol

Damn

Uh oh

It will sooon

Insiders have a vested interest in Regencell Bioscience Holdings' growth, as seen by their sizeable ownership

Yat-Gai Au owns 81% of the compan

WELL STATED, THANKYOU.
GL TRADING TODAY. STAY BLESSED

wants to do that super silly thing?

RGC: Indeed!! (And even the usually very aggressive trader --- Ms. 'Rheena'(??) --- only grabbed "25 shares" of that skyrocket!!! But she likely netted at least $700 bucks profit, anyway.)

EXACTLY, Colonel TIM!!! (Very-well-stated, Bro!!!) In passing, I use 'E-Turd', which at LEAST executes any kind of trade RAPIDLY, & for the best PRICE. But for ME --- way out here in San Diego --- the likes of "WeBull" just ain't gonna work!! Too damn EARLY in the morning. Hey Tim, when the likes of Orion's great "TheFinalCD" doesn't even know what to trade anymore, well, YOU get my point. The 'NASDAQ' markets these days make the old OTC look like it was a STABLE place to go.

THIS WAS JUST LESS THAN 20,000 VOLUME AND ALREADY UP 300%

INVEST****WHICH BROKERS ARE YOU USING*******TICKERS JUST FLEW OUT OF THE FRYING PAN FROM NOWHERE, BEFORE YOU KNOW IT 200 300 400 600%/ *****A ND FEW ARE MAKING A KILLING , NO JOKES, KILLINGS THAT WILL BLOW YOUR MIND AWAY.
BROKERS MATTER, SCANNERS MATTER, ALERTS MATTER, AND NONE HOLD THE CHARGE. QUICKEST PUMP AND LIGHNING LIKE DUMP. GOOD LUCK BRO******* AND GOD IS REAL AND TRINITY IS UNIVERSALLY, DIVINELY SOLIDIFIED AND PRAISED.

RGC: Hey, Capt. TIM!!! (What a ZOO!! Every day now, about THREE monster 400%-to-600% skyrockets, all of which are leaving ME patently BEWILDERED, Dude!!! And I ain't the only one.)

PS: And tell Orion's "AUGUSTA" that his noctural DREAM of months ago --- about Ms.. HARRIS becoming PRESIDENT --- is about to come true!!! The 'Good Lord' willing that is, & I'm a full-blown ATHEIST saying that. And one last time, it is TOO BAD that the sniper missed you-know-who.)

Alright so raise your hand who was responsible for this

I THOUGHT "INVEST" RETIRED********** WHAT ARE U STILL DOING HERE MONEY MAN********INVEST FOR PRESIDENT HARRIS VICE PRESIDENT****

RGC: Ya-all scored MONSTER-TIME here, RIGHT???!!! I totally MISSED it!!! (Post here how much BANK ya-all made!!! GOD-BLESS!!! CONGRATS!!! And I ain't joking!!!)

PGHL IPO also

LOL

Oh boy

finally moved $10 to $18 now $25(19.92 x 28.66), my guess $100 lets see where my 25 shares go ,LOL

Hahahahaha

They put a t1 on this yet? Hasn’t traded in almost a hour

LOL

(NASDQ: $RGC ) #RGCgivingback - Anyone, Anywhere, You Can Make A Difference! rgcfoundation.org

https://www.dropbox.com/scl/fi/5giusloz22bsl5zax1go6/RGCgivingback-Anyone-Anywhere-You-Can-Make-A-Difference-rgcfoundation.org-2023.docx?dl=0&rlkey=f4alsbg6ehuppb39w029y4u7e

$RGC - 81% of Regencell Bioscience Holdings Limited (NASDAQ:RGC) is owned by insiders, and they've been buying recently

https://finance.yahoo.com/news/81-regencell-bioscience-holdings-limited-105517095.html

Pretty $olid

$RGC Regencell Bioscience: Transforming Patient Treatment with Innovative Biotech Solutions
The CEO of Regencell, Yat-Gai Au, has expressed his goal and vision for the future of the company, with the aim of transforming the way patients are treated. Despite the current financial difficulties faced by the market and economy, Regencell is poised to lead the charge in the biotech and bioscience industry, which has seen a significant influx of investments in recent times.

The past few months have been a trying time for investors, as the ongoing health crisis and political unrest have taken a toll on market and economic performance. The Federal Reserve's decision to raise interest rates and the nation's spiraling inflation, which has reached a 40-year high, has only added to the uncertainty and instability.

However, there are industries that are trying to attract investors with innovative strategies, as businesses aim to increase their impact and market domination. The biotech and bioscience industry is one such example, with many investors willing to take a chance on some of the shares in their portfolio to mitigate the effects of a potential recession.

A McKinsey research report from 2022 showed that biotech companies raised more than $34 billion globally in 2021, a significant increase from the $16 billion raised in 2020. This trend is further reflected in the continuous investment in therapeutic-based biotech startups by venture capital companies, which amounted to more than $52 billion between 2019 and 2021, even during the height of the pandemic.

Yat-Gai Au, who is the founder and CEO of Regencell Bioscience, has been taking a proactive approach to securing the future of the company. He has made purchases of ordinary company shares from the open market since Regencell was listed on NASDAQ in mid-July 2021. This move is aimed at dealing with the short and disrupted investing schemes used on the company's stocks, which can have a negative impact on overall stock performance if left unchecked.

The CEO's commitment to the future of Regencell is evident, as he has invested millions of his personal funds to purchase company shares. He is fully devoted to his plan and the future of the company, which is poised to make a major impact in the biotech and bioscience industry. With Regencell's cutting-edge research and development in the field of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and infectious diseases, the company is well positioned to change the way patients are treated and improve lives.

For more information about Regencell Bioscience and their work, visit their website at www.regencellbioscience.com and stay updated on their latest developments.

Revolutionizing ADHD and ASD Treatment with Regencell's Natural TCM Formulae

Millions of children globally are diagnosed with ADHD and/or Autism Spectrum Disorder (ASD), and many of them also suffer from additional mental, emotional, or behavioral conditions. While therapy and medication are commonly prescribed, these drugs can come with side effects such as sleep disturbances, appetite loss, headaches, stomach issues, and mood swings.

To address this unmet need for a natural and holistic treatment for neurocognitive disorders, Regencell is conducting efficacy trials on its standardized Traditional Chinese Medicine (TCM) formulae.

Regencell's TCM Formulae

Regencell's TCM formulae are all-natural liquid TCM treatments for ADHD and ASD. In its latest trial, the formulae were given to children twice daily for three months.

Developed by a TCM practitioner based on the Sik-Kee Au TCM Brain Theory®, the formulae contain only natural ingredients and have been used for over 30 years to treat a range of neurological illnesses and disorders, including ADHD and ASD, with positive results.

According to the TCM brain theory, disruptions in blood flow and damage to the central nervous, endocrine, and circulatory systems can impact the production of hormones and transmission of neurotransmitters like melatonin, dopamine, and norepinephrine. This results in poor encoding and decoding of functions, causing the social behaviors characteristic of ADHD and ASD.

Regencell Bioscience Holdings is an early-stage company focused on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders, including ADHD and ASD, and infectious diseases like COVID-19. The company has already completed a study on personalized TCM formulae for ADHD and ASD in Hong Kong and plans to launch three liquid-based TCM formulae for mild, moderate, and severe cases of ADHD and ASD, starting in Hong Kong and expanding to other markets as appropriate. Regencell has also formed a joint venture to offer COVID-19 treatments in various countries in Asia, India, Japan, Australia, and New Zealand. For more information, visit their websites at www.regencellbioscience.com and www.regencellasia.com.

Revolutionizing ADHD and ASD Treatment with Regencell's Natural TCM Formulae

Millions of children globally are diagnosed with ADHD and/or Autism Spectrum Disorder (ASD), and many of them also suffer from additional mental, emotional, or behavioral conditions. While therapy and medication are commonly prescribed, these drugs can come with side effects such as sleep disturbances, appetite loss, headaches, stomach issues, and mood swings.

To address this unmet need for a natural and holistic treatment for neurocognitive disorders, Regencell is conducting efficacy trials on its standardized Traditional Chinese Medicine (TCM) formulae.

Regencell's TCM Formulae

Regencell's TCM formulae are all-natural liquid TCM treatments for ADHD and ASD. In its latest trial, the formulae were given to children twice daily for three months.

Developed by a TCM practitioner based on the Sik-Kee Au TCM Brain Theory®, the formulae contain only natural ingredients and have been used for over 30 years to treat a range of neurological illnesses and disorders, including ADHD and ASD, with positive results.

According to the TCM brain theory, disruptions in blood flow and damage to the central nervous, endocrine, and circulatory systems can impact the production of hormones and transmission of neurotransmitters like melatonin, dopamine, and norepinephrine. This results in poor encoding and decoding of functions, causing the social behaviors characteristic of ADHD and ASD.

Regencell Bioscience Holdings is an early-stage company focused on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders, including ADHD and ASD, and infectious diseases like COVID-19. The company has already completed a study on personalized TCM formulae for ADHD and ASD in Hong Kong and plans to launch three liquid-based TCM formulae for mild, moderate, and severe cases of ADHD and ASD, starting in Hong Kong and expanding to other markets as appropriate. Regencell has also formed a joint venture to offer COVID-19 treatments in various countries in Asia, India, Japan, Australia, and New Zealand. For more information, visit their websites at www.regencellbioscience.com and www.regencellasia.com.

Revolutionizing ADHD and ASD Treatment with Regencell's Natural TCM Formulae

Millions of children globally are diagnosed with ADHD and/or Autism Spectrum Disorder (ASD), and many of them also suffer from additional mental, emotional, or behavioral conditions. While therapy and medication are commonly prescribed, these drugs can come with side effects such as sleep disturbances, appetite loss, headaches, stomach issues, and mood swings.

To address this unmet need for a natural and holistic treatment for neurocognitive disorders, Regencell is conducting efficacy trials on its standardized Traditional Chinese Medicine (TCM) formulae.

Regencell's TCM Formulae

Regencell's TCM formulae are all-natural liquid TCM treatments for ADHD and ASD. In its latest trial, the formulae were given to children twice daily for three months.

Developed by a TCM practitioner based on the Sik-Kee Au TCM Brain Theory®, the formulae contain only natural ingredients and have been used for over 30 years to treat a range of neurological illnesses and disorders, including ADHD and ASD, with positive results.

According to the TCM brain theory, disruptions in blood flow and damage to the central nervous, endocrine, and circulatory systems can impact the production of hormones and transmission of neurotransmitters like melatonin, dopamine, and norepinephrine. This results in poor encoding and decoding of functions, causing the social behaviors characteristic of ADHD and ASD.

Regencell Bioscience Holdings is an early-stage company focused on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders, including ADHD and ASD, and infectious diseases like COVID-19. The company has already completed a study on personalized TCM formulae for ADHD and ASD in Hong Kong and plans to launch three liquid-based TCM formulae for mild, moderate, and severe cases of ADHD and ASD, starting in Hong Kong and expanding to other markets as appropriate. Regencell has also formed a joint venture to offer COVID-19 treatments in various countries in Asia, India, Japan, Australia, and New Zealand. For more information, visit their websites at www.regencellbioscience.com and www.regencellasia.com.

$RGC :Thriving Biotech and Bioscience Industry
The financial markets have been on a roller coaster ride over the past few months, with investors navigating a volatile landscape of economic uncertainty, political tension, and global health crises. As the world continues to grapple with the ongoing COVID-19 pandemic, many industries have been hit hard by the resulting economic downturn.

Despite these challenges, some sectors have managed to weather the storm and even thrive in these trying times. One such industry that has seen significant growth in recent months is the biotechnology and bioscience sector.

According to a 2022 McKinsey research report, biotech companies were able to raise more than $34 billion globally in 2021, nearly doubling the $16 billion raised in 2020. This trend is likely to continue as investors look for growth opportunities in an otherwise uncertain market.

One company that has stood out in this space is Regencell Bioscience (NASDAQ: RGC), a Hong Kong-based biotech firm focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.

Since its listing on NASDAQ in mid-July 2021, Regencell has seen its share prices climb by approximately 247.31%, even as market conditions have slowed down over the past year. This impressive performance is a testament to the company's solid fundamentals and growth prospects.

Regencell's focus on TCM is particularly noteworthy, as the use of complementary and alternative medicine (CAM) has been on the rise in recent years. According to a study conducted by the U.S. Centers for Disease Control (CDC), nearly 40% of American adults used some form of CAM medication in 2004. With the advancements in technology and AI, this figure is likely to be even higher today.

Regencell's innovative approach to TCM is reflected in its impressive list of clinical trials and research programs. For example, the company's EARTH Trial has shown that RGC-COV19TM, an TCM formula, is an effective treatment for the alleviation and elimination of COVID-19 symptoms within 6 days. This not only helps to reduce the risk of hospitalization and death, but also demonstrates the potential of TCM in addressing unmet medical needs.

The company's leadership team, led by founder and CEO Yat-Gai Au, has also been instrumental in its success. With a shared vision and a team of experts dedicated to developing safe and effective treatments, Regencell is well-positioned to continue its growth trajectory in the years to come.

In fact, Au has been consistently buying shares of RGC in the open market, using his own money to alleviate short and distort investing schemes used on the company's stocks which in the long term can negatively hurt overall stock performance. This is a clear indication of the CEO's belief in the company's future and its potential.

Overall, Regencell Bioscience is an exciting growth-oriented company with a clear vision to help people improve their lives through TCM. As the world continues to face economic and health challenges, companies like Regencell that offer innovative solutions and a strong leadership team are well-positioned to succeed in the long-term. Investors looking for growth opportunities in the biotech sector should definitely keep an eye on RGC.

https://www.benzinga.com/general/entertainment/22/05/27291606/sector-rotation-and-9-stocks-to-watch-during-a-recession?SNAPI

$RGC: A Driving Force in the Thriving Biotech Industry

The biotechnology and bioscience industry has been on a roll in recent months, with many companies experiencing unexpected success despite the faltering stock market. Analysts attribute this success to a combination of factors, including advancements in data science, machine learning, and instrumentation, which are facilitating quicker and more reliable drug development breakthroughs.

According to a 2022 McKinsey research report, biotech companies were able to raise more than $34 billion globally in 2021, doubling the $16 billion raised in 2020. This trend is expected to continue, with venture capital companies investing more than $52 billion in therapeutic-based biotech companies between 2019 and 2021.

One such company that has been making waves in the industry is Regencell Bioscience. As an early-stage bioscience company, Regencell is focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations. The company has become a leader in the field, and is striving to alleviate the unmet medical needs of millions of people around the world.

Regencell went public through an Initial Public Offering on the stock market in July 2021, and since then, its share prices have climbed by approximately 247.31%, despite market conditions slowing down since the start of the year. The company's chairman and CEO, Yat-Gai Au, has also been actively buying company shares from the open market to alleviate short and distort investing schemes, which can negatively affect overall stock performance in the long term.

The biotechnology and bioscience industry is proving to be a reliable investment, even in times of economic downturn. As the sector continues to advance and innovate, it is likely to play a significant role in driving the next bull market. With companies like Regencell leading the way, the future looks bright for the industry.
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

Long Covid is particularly complicated because there's no set list of symptoms. The Centers for Disease Control and Prevention notes a wide array of ongoing health problems that could include fatigue, shortness of breath, neurological and digestive symptoms as well as joint or muscle pain.

But so far, large companies are shying away from treating the condition.

Instead, small companies have taken up the mantle in long Covid treatment. They include Axcella Therapeutics (AXLA), First Wave BioPharma (FWBI), Ampio Pharmaceuticals (AMPE), Regencell Bioscience (RGC), Aim ImmunoTech (AIM), Tonix Pharmaceuticals (TNXP) and privately held Humanetics.

Long Covid Treatments: Up To 23 Million
Axcella, Ampio, Regencell and Tonix include long Covid treatments in their pipelines. First Wave is working on gastrointestinal side effects of Covid-19. Aim is testing out a treatment for Covid-19 patients with cancer. Humanetics is looking at lung injuries in Covid-19 patients.

The U.S. Government Accountability Office estimates up to 23 million people in the U.S. have long Covid. Research is still in its infancy, though. Not every Covid-19 case is diagnosed. Further, symptoms of long Covid vary and manifest themselves differently in each person.

The phenomenon isn't new. Survivors of the original SARS virus have reported chronic fatigue four years after the initial infection. The GAO estimates the post-Covid condition could push 1 million Americans out of the workforce, highlighting the need for long Covid treatments.

https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/

Sector rebalancing and nine stocks to keep an eye on amid a downturn.

The commonly accepted definition of a recession is a brief period of decreased commerce and manufacturing activity that is typically indicated by a dip in GDP over two consecutive quarters. The GDP shrank at an annual pace of 1.4 percent, down from 6.9 percent in the fourth quarter of 2021, according to the Bureau of Economic Analysis.

Although the macro picture is at best gloomy, it is important to comprehend the larger market dynamics that show where money is moving, such as the economic cycle and sector rotation.

A recession is a well-known natural component of an expanding economy and a stage of the economic cycle. The economy's transition from a growth stage to a recession and back to growth is known as the economic cycle. Since it directly affects stock prices in relation to corporate profitability, this is perhaps the factor with the most impact on the overall markets.

The numerous market sectors, each of which is responsive to a distinct stage of the cycle, are what link the stock market to the economic cycle.

Are you still perplexed? This ought should make it simple.

When the economy is expanding, some industries (such as real estate, consumer brands, and consumer goods) will perform better than others (Healthcare, Food, Consumer Staples, Utilities)

This is referred to as sector rotation or the movement of capital by investors throughout the course of the economic cycle.

Investors typically shift into less cycle-sensitive sectors, such consumer staples and utilities, when the economy is headed for a recession. These sectors are referred to as defensive sectors because they can provide a certain level of protection during a recession.

Some of those defensive names include:

Coca-Cola Co
Albertsons Companies Inc
Altria Group Inc
NRG Energy Inc
PG&E Corporation
Clearway Energy Inc
National HealthCare Corporation
HealthStream, Inc
Regencell Bioscience Holdings Ltd
On the other hand, after a recession ends, investors switch to stocks with a high cycle sensitivity, including industrials and consumer cyclicals.

This is because these sectors tend to benefit from economic growth and increasing consumer spending. Companies in these sectors, such as technology, consumer discretionary, and financials, typically see their profits and stock prices rise as the economy recovers.

When selecting stocks to invest in during a recession, it is important to consider a company's financial health, including its cash flow, debt levels, and overall financial position. In addition, it is important to consider the company's business model and how it may be affected by a recession.

As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.

Regencell Bioscience has a solid financial position, with a strong balance sheet and cash flow, making it well positioned to weather an economic downturn. The company also has a diverse business model, with a focus on both traditional and alternative medicine, which may be less affected by a recession than other industries.

https://www.benzinga.com/general/entertainment/22/05/27291606/sector-rotation-and-9-stocks-to-watch-during-a-recession?SNAPI

Regencell Bioscience is a Hong Kong-based company that is focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations. The company, led by its Chairman and CEO, Yat-Gai Au, has a clear vision to help people improve their lives through the use of TCM.

Regencell has become a leader in the field, spearheading the efforts to alleviate the unmet medical needs of millions of people around the world. Through their research and development programs, the company is working to develop treatments for ADHD and ASD patients, as well as for infectious diseases that affect the human immune systems.

Recently, the company has been gaining attention for its clinical trials, specifically the EARTH Trial, which has shown that RGC-COV19TM is an effective formula for the alleviation and elimination of COVID-19 symptoms within 6 days. This not only helps to reduce the symptoms for patients, but also reduces the risk of hospitalizations and death. These results have shown the effectiveness of TCM and alternative medicine in a hyper-modern and tech-driven world.

Yat-Gai Au believes that it is crucial to have the right team in place in order to remain true to the company's values and continue to head in the right direction. The Regencell team is dedicated to ensuring that their services and products are effective, safe, and useful for their patients.

In addition to their commitment to TCM research and development, Regencell is also focused on the commercialization of their products. The company recently went public through an Initial Public Offering on the stock market, and since then, the company's shares have grown by approximately 247.31%.

Despite turbulent market conditions, Regencell is comfortably poised for growth. Yat-Gai Au and the majority of shareholders are insider investors, and have recently invested more than $5.9 million in the company, showing their confidence in the future of Regencell Bioscience

https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

Regencell Bioscience's RGC-COV19TM: A Safe and Effective Solution for Reducing and Eliminating COVID-19 Symptoms.

Regencell began its investigational approach towards COVID-19 treatment when a friend of Regencell contracted COVID-19 in March 2020. To treat his friend, the TCM Practitioner used his proprietary TCM formula which he has been using over the past 30 years to treat various cold and flu patients, including during the 2003 SARS outbreak. The TCM Practitioner subsequently treated 9 voluntary COVID-19 patients in the United States using the proprietary TCM formula.

Study results showed that the treatment was effective. As Regencell has a mission to save lives, improve patients’ well-being and address unmet needs in the market, Regencell aims to make its natural and holistic treatment available to everyone in need.

From March 2020 to August 2021, Regencell set up protocols and procedures to conduct the EARTH efficacy trial in Malaysia and the United States.

RGC-COV19TM is designed to reduce COVID-19 symptoms such as fever, fatigue, cough, sore throat, runny nose, headache, nausea, chills, drowsiness, shortness of breath, persistent chest pain and muscle ache as the medicine works to (i) reduce and clear the mucus and phlegm from the upper respiratory system; (ii) dispel exterior viral pathogen via heavy sweats, urine and excrement; (iii) clear endogenous and liver heat; (iv) detox the liver; and (v) improve body circulation. By applying the TCM Practitioner’s “Sik-Kee Au TCM Brain Theory®”, RGC-COV19TM is also designed to remove blood clots from the brain and restore the patient's brain functions.

RGC-COV19TM (RGCA-CV01) is administered at 1 dose of RGCA-CV01-1Na (approximately 230ml) and 1 dose of RGCA-CV01-2Da (approximately 230ml) each time, with 1 dose of RGCA-CV01-1Na to be taken starting from the night of the first day of treatment and 1 dose of RGCA-CV01-2Da to be taken after lunch the next day, until symptoms are eliminated.

About RGC-COV19TM

RGC-COV19TM (RGCA-CV01) is an investigational, natural, orally administered liquid formula which aims to reduce and eliminate COVID-19 symptoms.

RGC-COV19TM is a natural formula designed by the TCM Practitioner according to the TCM Practitioner’s brain theory known as “Sik-Kee Au TCM Brain Theory®” and can be taken safely for two to three weeks. In conducting EARTH, the treatment was limited to 6 days in order to evaluate its efficacy in reducing and eliminating COVID-19 symptoms. The “TCM Practitioner” refers to our strategic TCM research partner, Sik-Kee Au, father of our founder and Chief Executive Officer.

According to the brain theory, brain functions depend on the oxygen level required for the brain to perform normal cognitive functions. For optimal brain performance, the heart needs to function normally to deliver sufficient oxygen to the brain. When the heart is weakened, the heart’s ability to deliver enough blood to circulate oxygen throughout the body is impaired. When this happens, brain functions are suppressed, resulting in a person experiencing fatigue, nausea, disorientation and reduced immune response.

RGC-COV19TM is designed to strengthen the heart’s functions. According to the brain theory, when the heart is strengthened, it increases blood flow and delivers more oxygen to the brain, resulting in reduced blood clots and restored brain functions. Regardless of the COVID-19 variant, the lungs and heart are where the coronavirus does much of its damage by setting off an inflammatory immune response that ravages infected and uninfected cells alike, leading to tissue scarring and oxygen deprivation which in turn suppress brain functions. RGC-COV19TM is formulated to generate more responsive cognitive functions which in turn stimulate the body’s own healing mechanism.

"Riding the Waves of Uncertainty: Finding Prosperous Stocks for Any Economy"

When the economy is uncertain, many investors search for recession-resistant stocks. These are companies that have a track record of performing well during economic downturns. While "recession-proof stocks" may not exist, investors can look for companies that have proven to be resilient during tough economic times.

Typically, recession-resistant stocks come from defensive sectors such as Consumer Staples, Utilities, and Health Care. These sectors are less affected by changes in interest rates and economic growth and often provide essential products and services that consumers continue to purchase during a recession. For example, people still need to buy groceries and pay for utility bills regardless of the state of the economy.
Currently, the Energy sector is performing well due to rising oil prices, supply chain concerns, and increased demand for gas, energy equipment, and services. However, it's worth noting that past performance is not a guarantee of future results.

When researching potential investments, it is important to look beyond surface-level returns and examine individual companies within a sector to identify those that may be well-positioned to weather an economic downturn. Some key factors to consider include a company's financial stability, diversified revenue streams, and strong management team.
For instance, in the Consumer Staples sector, companies like Coca-Cola, PepsiCo, Constellation Brands, Albertsons Companies, SpartanNash, Andersons and British American Tobacco that have a diversified product portfolio and a strong brand reputation may be better positioned to weather an economic downturn than those that rely heavily on a single product or brand. In the utilities sector, companies like NRG Energy, DTE Energy, OGE Energy, PG&E Corporation, Black Hills Corp, Exelon Corporation, Clearway Energy, NextEra Energy and First Solar, Inc that have a diverse mix of generation sources and regulated assets may be better insulated from market fluctuations than those that rely heavily on a single source of revenue.

In the Healthcare sector, companies like National HealthCare Corporation, Davita Inc, Alignment Healthcare Inc, Sophia Genetics, Computer Programs & Systems, HealthStream, Viatris, Regencell Bioscience Holdings and Prestige Consumer Healthcare that have a strong pipeline of products in development and a track record of innovation may be better positioned to weather an economic downturn than those that rely heavily on a single drug or therapy.

It's worth noting that even though these stocks are considered "recession-resistant" it doesn't mean they can't go down, but they tend to be less affected than other sectors. It's also important to diversify your portfolio and not to put all your eggs in one basket. Always consult with a financial advisor and conduct your own research before making any investment decisions.

Original link:

https://www.benzinga.com/news/small-cap/22/05/27083377/27-recession-resistant-stocks-to-hold-through-tough-times

"The Ins and Outs of CEO Stock Purchases: A Look at Regencell Bioscience"

A CEO may buy shares in their own company for a variety of reasons, including seeing the stock as undervalued and wanting to demonstrate confidence in the company's prospects to the market. When a CEO buys shares in their own company, it sends a signal to the market that they believe the stock is undervalued and that the company has a bright future ahead. This can help to boost investor confidence and drive up the stock price.

Another reason for a CEO to buy shares in their own company is to align their interests with those of shareholders. Some companies may require their senior executives to purchase a certain number of shares in the company in order to ensure that they are acting in the best interests of the shareholders. By holding a significant number of shares in the company, a CEO is more likely to make decisions that will benefit the company and its shareholders in the long-term.

In the case of Regencell Bioscience, the company's Chairman and CEO, Mr. Yat-Gai Au, has taken a particularly transparent and shareholder-aligned approach. Since the company's incorporation in October 2014 up to the IPO, the company has been fully funded by Mr. Au. Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50. He pledged not to draw salary and bonus of more than USD $1 until the company reaches USD $1 billion market capitalization. He also will not award share options for himself.

Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased 49,010 shares (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million). This shows his commitment to the company, and it clearly demonstrates that his interests are aligned with those of the shareholders. By investing his own money in the company, he is also signaling to the market that he believes in the company's future and that the stock is undervalued. This can help to boost investor confidence and drive up the stock price. Overall, the CEO buying shares in their own company is a positive signal for investors and can be a sign of a company with a bright future ahead.

https://www.forbes.com/advisor/investing/stock-buyback/#:~:text=A%20stock%20buyback%20is%20when,fund%20operations%20and%20other%20investments

https://www.quora.com/Why-would-a-CEO-buy-shares-in-their-company-when-the-company-stock-is-selling-off/answer/William-Elliott-29?ch=10&oid=336350002&share=85576911&srid=hIzcnI&target_type=answer

https://newsfilter.io/articles/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo-3b36a9b6af854a3aa5240d3148ccbd

"Exploring the Benefits of AI and VR in Healthcare and Alternative Medicine: Insights from RGC CEO"

As the world of technology continues to evolve at a rapid pace, healthcare providers and alternative medicine practitioners are looking for ways to safely adopt new innovations to improve patient outcomes. Artificial Intelligence (AI) and Virtual Reality (VR) are at the forefront of this movement, and businesses that fail to maximize their capabilities risk falling behind in the highly competitive marketplace.

The rise of the Internet-of-Things (IoT), mobile communication, and 5G tools have greatly contributed to the expansion of these technologies across multiple fields. While initially, it was believed that these developments would mainly be used in advanced industries such as military, security, engineering, architecture, and aviation, the need for state-of-the-art tools has quickly manifested itself within the healthcare and alternative medicine market.

AI and Traditional Chinese Medicine (TCM) are a perfect example of how these technologies can be used together in a complementary way. By incorporating AI into TCM, practitioners can make more accurate diagnoses and develop more effective treatment plans. Additionally, AI can be used to monitor patients' progress and adjust treatment plans as needed.

In the sphere of virtual reality, it's now possible for clinical and medical personnel to combine different technologies to enhance their multisensory working environment. The adoption of virtual or augmented reality tools has also been found to help alleviate stress, anxiety, and burnout experienced by healthcare workers. Telemedicine has become increasingly popular during the pandemic, as it allows for online medical consultations, enabling doctors to continue seeing and treating patients from the comfort of their own homes.

While the ongoing development and opportunities seem endless, it is essential to ensure that these technologies are safely adopted in the healthcare and alternative medicine fields. The benefits are clear, but the security and privacy of patients must be a top priority. As we continue to explore these exciting new frontiers, it is vital to work together and learn from one another to achieve the best possible outcomes for patients.

https://www.entrepreneur.com/en-in/technology/how-can-healthcare-and-alternative-medicine-safely-adopt/439152

$RGC - Growth-oriented company with a clear vision to help people improve their lives.

As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.

"For our company to remain true to what we believe in, and continue to head in the right direction, it's critical to have the right set of people with a shared value of interests. Our team develops programs and leads scientific trials to ensure our services and products are effective, safe and useful," shares Yat-Gai.

The company has grown to be more than just a research and development facility for the treatment of neurocognitive disorders and degenerations. "It's paving the way for extraordinary improvements in TCM to be mainstream. Why should only a small group of people or communities have access to these groundbreaking treatments?"

In a recent clinical study - EARTH Trial - results showed that RGC-COV19TM is an effective formula for the alleviation and elimination of COVID-19 symptoms within 6 days. This in return helps to reduce the risks of hospitalizations and death. The rigorous trials have shown the effectiveness of TCM and alternative medicine in a hyper-modern and tech-driven world.

https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

The Downturn For Big Pharma

The bullish turn for biotech since June has come in lockstep with a downturn for Big Pharma stocks. Just three months ago, the pharmaceuticals group ranked No. 34 out of 197. It has now tumbled 100 spots, ranking No. 134.
Earlier this year, rising interest rates and inflation worries sent investors
scrambling for less risky stocks. In the world of medicine, Big Pharma fits that bill. Pharmaceutical companies sell widely used products like cholesterol and cancer drugs.

Biotech companies, on the other hand, are working on cutting-edge treatments where losses outnumber game-winning touchdowns. Then, investors “cared a lot more about businesses that have predictable cash flows today, as opposed to the businesses that have the promise of really big predictable cash flows in the future,” Swalla said.
“I think biotech and technology stocks suffered the same fate from an institutional-investor standpoint.” But now, experts say the paradigm
is shifting from a “risk off” environment favoring companies with stable, predictable cash flows to more growth-oriented plays.

And when it comes to growth, biotech tends to be among the most eye-catching segments.
Lee Brown, sector lead for health care at research firm Third Bridge,
says biotech stocks could actually offer investors a safe haven amid
economic uncertainty. “If you’re worried about the economic climate for next year, then being in more idiosyncratic growth sectors is right out of the portfolio manager playbook,” he told IBD. Eric Schiffer, who chairs private
equity firm The Patriarch Organization, has a more measured view. He says biotech remains tied to macroeconomic woes, but these stocks have been more beat-up than others and could offer investors a low point for entry. “What we do know is there’s incredible discoveries ahead that will be worth millions of dollars,” he said. “We’re in a cycle. This is a cycle that will see a bull period ahead. We just don’t know when. If investors have a long enough ride, they can do fine. They’re getting in at great valuations.”
https://www.investors.com/

Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune system such as COVID-19. Regencell has completed its first research study using personalized TCM formulae for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently in other markets as it deems appropriate. The Company has formed a joint venture to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand. For more information, please visit www.regencellbioscience.com and www.regencellasia.com.

Despite the stock market downturn, the biotech industry has shown resilience and is expected to continue growing, according to experts.

Numerous biotech firms, from top-rated Catalyst Pharmaceuticals to powerhouses like Neurocrine Biosciences and BioMarin Pharmaceutical, down to relatively unheard-of Karuna Therapeutics, are soaring like it's a fresh bull market despite the faltering stock market. The unexpected success of the biotech companies is the result of numerous factors, not just one spark. Analysts believe that is encouraging for their long-term viability.

Regardless of how stock prices fluctuate on any given day, Loncar told Investor's Business Daily that the underlying news that determines whether biotech is moving forward or backward has recently been all positive. "Everything is pointing in the right direction," He points out that, beginning in early last year, biotech equities were the first sector to experience a decline. They are now among the first people to turn around. The biotech sector group was placed 143rd out of 197 industries just six months ago, placing it in the lowest 25% of all industry groups. Since then, the sector's top biotech stocks have propelled it to a sixth-place ranking and a combined value of $1.2 trillion.

Can biotech drive the following bull market, then? According to Thomas Swalla, CEO of privately held Dotmatics, "It should." Dotmatics creates software to support businesses in the life sciences. Swalla points out that data science, machine learning, and instrumentation are all facilitating quicker and more reliable drug development breakthroughs. IBD quoted him as saying, "I absolutely don't see any reason why biotech can't be a significant influence in the future.

Many investors, who are willing to risk some of their portfolio shares to help stabilize their position in the event of a recession, have placed major bets on the biotechnology and bioscience industry in recent months. According to a 2022 Mckinsey research report, biotech companies were able to raise more than $34 billion globally in 2021, doubling the $16 billion raised in 2020.

The same report found that between 2019 and 2021, even as the pandemic took hold of the global economy throughout the greater part of 2020, venture capital companies still invested more than $52 billion in therapeutic-based biotech companies.

Since Regencell was listed on NASDAQ in mid-July 2021, Regencell Bioscience founder and CEO, Yat-Gai Au has made purchases of ordinary company shares from the open market to alleviate the short and distort investing schemes used on the company's stocks which in the long term can negatively hurt overall stock performance. With millions of his personal finances already spent to purchase company shares, Yat-Gai Au shared why he's fully committed to this strategy and the future of the company.

About Regencell Bioscience
As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.

Regencell has become a leader that's spearheading forward as a global influence that looks to alleviate the unmet medical needs of millions of people around the world. Through their efforts, the company researches and develops treatments for ADHD and ASD patients and infectious diseases that affect the human immune systems.

On July 16, 2021, the company went public through an Initial Public Offering on the stock market with 2.3 million ordinary shares at a public offering price of $9.50. Over the last 12 months of trading, share prices have climbed by approximately 247.31% even though market conditions have been slowing since the start of the year.

Amid a flurry of investors now locking up high-yielding stocks as a way to secure their portfolios, RGC has solidified itself in the market, while spearheading the development and commercialization of TCM.

https://www.investors.com/
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

A significant chance for exponential returns could be found in biotech stocks.

Biotech stocks are always in the spotlight as the sector itself has been the source of significant disruptions for the global healthcare system. Long sought after by both high-risk investors and low-risk investors, biotechnology stocks offer something that other stocks do not: highly speculative opportunities. Because many of these companies are involved in early phase trials of things like novel drugs, a positive result at any phase can end up producing a favorable reaction in the stocks market. And for biotech stock investors, this could be a big opportunity for exponential gains.

Regencell Bioscience, an early-clinical bioscience company which focuses on the research and development of Traditional Chinese Medicine (TCM) to holistically treat neurocognitive disorders and also infectious diseases which affects the immune system such as COVID-19.

The company have been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. The goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the treatment of these disorders. $rgc aim to achieve improvements in both symptoms and overall health of patients as compared to currently available medications in the market. They are passionate about transforming the lives of patients, their families and caregivers and help them feel their best physically, mentally and emotionally!

Nasdaq Listing

On July 16, 2021, the ordinary shares began trading on the Nasdaq Capital Market. The company raised net proceeds of approximately $19.3 million from the initial public offering of 2,300,000 ordinary shares at a public offering price of $9.50 per share. They plan to use these proceeds to fund for the second research study (currently ongoing), TCM formulae and products, staff salaries, product and intellectual property registrations, facilities rental, renovations and equipment, for working capital and other general corporate purposes.
https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html

Why Is This Biotech Stock Worth a Look?

RGC launched a follow-up research for their experimental liquid formula RGC-COV19TM in the treatment of COVID-19 symptoms on May 18, 2022. (EARTH-B Trial). The second study expanded on the encouraging findings from the initial EARTH experiment (EARTH-A Trial), which was carried out in 2020–2021. In the two studies, 95.5 percent of the participants (n=81) reported complete symptom relief six days after therapy, with the exception of occasional coughing and loss or reduction in sensation of taste and/or smell (sensory dysfunction).

RGC anticipates publishing data from its second clinical research of its standardised TCM formula for the treatment of ASD and ADHD in the coming months.

In order to set standards for therapy, dosing, adverse effects (AEs), and assessing patient response in a methodical and reproducible manner, Regencell Bioscience's initial clinical study was created. Seven adolescents with clinically confirmed ASD or ADHD, ranging in age from five to eleven, participated in the 2018–2019 study. Subjects got a personalized TCM formula for up to three months after stopping all current treatments and medications. Parental interviews and four validated assessment tools, such as the Autism Treatment Evaluation Checklist (ATEC), Gilliam Autism Rating Scale (GARS), Vanderbilt ADHD Diagnostic Parent Rating Scale (VADRS), and Pelham (SNAP)-IV 26-item Parent Rating Scale, were used to gauge the responses of the patients (SNAP-IV-26). During the course of treatment, all seven patients showed a reduction in symptoms on all four scales.

The second clinical trial assesses how three standardized TCM formula mixes (for mild, moderate, and severe impairment) respond to children in the same age group. Weekly practitioner meetings, twice daily medication for three to twelve months, and monthly assessments are all part of the study's design. The outcomes will be used to submit a proprietary Chinese medicine (pCm) registration application in Hong Kong, making the product available for purchase both over the counter and in other clinic.

To support its findings, Regencell is concentrating on its clinical research. Through these initiatives, the infrastructure for manufacturing and the supply chain that is needed to obtain pCm registration will be built. The commercialization of Regencell Bioscience's standardised formulations and pCm registration in Hong Kong are both subject to a four-year timeline. A lot of tasks lie ahead for the company:

•Finishing its second clinical trial and reviewing outcomes.
• Running more clinical studies to support the use of its patented formulas for ASD/ADHD and other uses.
• Getting IP protection in Hong Kong and other markets through the acquisition of patents and other types of IP.
• Setting up a manufacturing infrastructure and supply chain that complies with registration criteria.
• Compiling and filing paperwork for pCm approval.
• Develop the infrastructure and marketing and distribution plan.
We are encouraged by RGC's thoughtful, methodical approach to developing its therapies and communicating its progress to shareholders, which we believe may be a sign of greater things to come as it moves towards commercialization. RGC's steady share price ascent in recent weeks.
• Completing its second clinical trial and evaluating results.
• Conducting additional clinical trials to support its proprietary formulae in ASD/ADHD and other applications.
• Obtaining patents and other forms of IP protection in Hong Kong and other markets.
• Establishing manufacturing capability and supply chain that will meet registration requirements.
• Assembling and filing documentation for pCm approval.
• Build out its marketing and distribution strategy and infrastructure.
•
RGC’s steady share price ascension in recent weeks may be a sign of greater things to come as its moves towards commercialization, we are encouraged by its thoughtful, systematic approach to developing its therapies, and communicating its progress to shareholders.

https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html

$RGC CEO spent millions of his personal finances on purchasing company shares.

Since the company went public, Yat-Gai, the CEO of Regencell Bioscience $RGC, has noticed that short and distort organizations or individuals are starting to affect their stock price and sentiment.

"Companies like ours are not given the opportunity to prove themselves since the culprits are driving down the value of smaller companies, causing the market and general public to lose its confidence. This causes damage to our company, particularly the patients, some who are desperate for a solution," he said.

To help mitigate the negative effects of such short-term schemes, Yat-Gai managed to purchase more than $5.9 million worth of ordinary company shares. To date, Yat-Gai Au is the majority shareholder, with an 81% stake in the company. This leaves around 19% of shares owned by other shareholders.

"To date, I have spent millions of my personal finances on purchasing RGC shares. My most recent purchase was worth $886,000 of RGC shares at an average price of US$39.48, increasing my shareholdings by 0.2%. I believe in the company and its future and intend to continue to put my money where my mouth is and increase my shareholdings."

Seeing as majority ownership is held within the company, oftentimes referred to as 'Insider Ownership,' it allows them to have better control over critical decision-making issues that can help fast-track the company's overall development goals.

"The decision to repeatedly purchase RGC shares over the last several months is to support and ensure the potential of the company can be met for years to come. We've vested a lot of time, energy, and resources in Regencell, and we're well aware of the potential difference it can make in the field of alternative medicine. I believe that as I lead the way our company will be able to meet the goals we've set out to achieve within the coming years."

The long-term transactions not only give the company better control over critical decision-making but enables them to boost investor sentiment.

https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

"Biotech Sector Proves Resilient Amid Faltering Stock Market, Experts Predict Continued Growth"
Numerous biotech firms, from top-rated Catalyst Pharmaceuticals to powerhouses like Neurocrine Biosciences and BioMarin Pharmaceutical, down to relatively unheard-of Karuna Therapeutics, are soaring like it's a fresh bull market despite the faltering stock market. The unexpected success of the biotech companies is the result of numerous factors, not just one spark. Analysts believe that is encouraging for their long-term viability.

Regardless of how stock prices fluctuate on any given day, Loncar told Investor's Business Daily that the underlying news that determines whether biotech is moving forward or backward has recently been all positive. "Everything is pointing in the right direction," He points out that, beginning in early last year, biotech equities were the first sector to experience a decline. They are now among the first people to turn around. The biotech sector group was placed 143rd out of 197 industries just six months ago, placing it in the lowest 25% of all industry groups. Since then, the sector's top biotech stocks have propelled it to a sixth-place ranking and a combined value of $1.2 trillion.

Can biotech drive the following bull market, then? According to Thomas Swalla, CEO of privately held Dotmatics, "It should." Dotmatics creates software to support businesses in the life sciences. Swalla points out that data science, machine learning, and instrumentation are all facilitating quicker and more reliable drug development breakthroughs. IBD quoted him as saying, "I absolutely don't see any reason why biotech can't be a significant influence in the future.

Many investors, who are willing to risk some of their portfolio shares to help stabilize their position in the event of a recession, have placed major bets on the biotechnology and bioscience industry in recent months. According to a 2022 Mckinsey research report, biotech companies were able to raise more than $34 billion globally in 2021, doubling the $16 billion raised in 2020.

The same report found that between 2019 and 2021, even as the pandemic took hold of the global economy throughout the greater part of 2020, venture capital companies still invested more than $52 billion in therapeutic-based biotech companies.

Since Regencell was listed on NASDAQ in mid-July 2021, Regencell Bioscience founder and CEO, Yat-Gai Au has made purchases of ordinary company shares from the open market to alleviate the short and distort investing schemes used on the company's stocks which in the long term can negatively hurt overall stock performance. With millions of his personal finances already spent to purchase company shares, Yat-Gai Au shared why he's fully committed to this strategy and the future of the company.
About Regencell Bioscience
As an early-stage bioscience company, Regencell Bioscience (NASDAQ: RGC) is a Hong Kong-based company focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations.

Regencell has become a leader that's spearheading forward as a global influence that looks to alleviate the unmet medical needs of millions of people around the world. Through their efforts, the company researches and develops treatments for ADHD and ASD patients and infectious diseases that affect the human immune systems.

On July 16, 2021, the company went public through an Initial Public Offering on the stock market with 2.3 million ordinary shares at a public offering price of $9.50. Over the last 12 months of trading, share prices have climbed by approximately 247.31% even though market conditions have been slowing since the start of the year.

Amid a flurry of investors now locking up high-yielding stocks as a way to secure their portfolios, RGC has solidified itself in the market, while spearheading the development and commercialization of TCM.

https://www.investors.com/
https://www.ibtimes.com/regencell-ceo-shares-his-vision-insights-aims-change-way-patients-are-treated-3600337

Things to Consider When Analyzing Small-Cap Stocks
Management Quality: A competent management team is essential for any company, let alone a smaller one trying to establish itself in the market. Potential investors should undertake some basic online research on the key people within the company, such as the CEO and chief financial officer (CFO). Do they have a track record of running successful businesses? Also, see if the leadership team owns shares in the company. Company insiders owning stock indicates a commitment to success and aligns their interests with those of the shareholders.

Growing Sales: Small-cap companies typically have limited cash flow—therefore, they must generate healthy sales. As a rule of thumb, small-cap investors should look for stocks with an annual revenue growth rate of at least 20%, which indicates that a company has the potential for disruptive innovation within its industry and is well positioned to generate a future profit. Investors can find this information on Yahoo! Finance under the "Financials" tab, which shows a company's revenue for the past three years.

High Operating Margins: A company's operating margin represents how efficiently it can generate profit through its primary operations before paying interest and tax. When investing in small caps, it is a good idea to look for consistently increasing operating margins, as this indicates that a company is good at turning sales into profits.

Advantages of Small-Cap Stocks
Growth Potential: Small-cap stocks provide investors with significant upside by getting in early before a company potentially goes on to become an industry leader. Moreover, small-cap stocks with a market capitalization of under $1 billion can double in value much easier than companies like Amazon or Apple that have $1 trillion-plus market caps, as it takes far less money to move their share price. Additionally, a small-cap stock that goes on to realize rapid growth can gain the attention of Wall Street analysts and institutional investors, which can increase shareholder returns even further.

Less Competition from Larger Investors: Institutional investors, such as banks, hedge funds, and REITs, typically stick to investing in large-cap stocks, often overlooking many small-cap opportunities. This allows retail investors to buy the story of a future company of tomorrow without competing with traditional Wall Street money.

One ticker that has a small market cap ($412.35M) and a CEO who is holding 81% of the stock is Regencell Bioscience ($RGC).
To get a sense of who is truly in control of Regencell Bioscience Holdings Limited (NASDAQ:RGC), it is important to understand the ownership structure of the business. With 81% stake, individual insiders possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises.

Data shows that insiders recently bought shares in the company and they were rewarded after market cap rose US$64m last week.

Let's take a closer look to see what the different types of shareholders can tell us about Regencell Bioscience Holdings.

What Does The Lack Of Institutional Ownership Tell Us About Regencell Bioscience Holdings?
Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them.

There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company.
https://www.investopedia.com/investing/top-small-cap-stocks/